Drug pipeline
Explore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Outer membrane protein OmpK36 is a major non-selective porin in the Gram-negative bacterium Klebsiella pneumoniae, homologous to Escherichia coli OmpC. It forms a trimeric beta-barrel channel that facilitates the passive diffusion of hydrophilic nutrients and small molecules, including beta-lactam antibiotics such as carbapenems and cephalosporins, across the outer membrane. OmpK36 is a critical determinant of antibiotic susceptibility; mutations that constrict the pore (such as Gly-Asp insertions in the L3 loop) or downregulate its expression significantly reduce drug entry, driving high-level resistance in carbapenemase-producing strains. Beyond its role in drug resistance, OmpK36 serves as a primary or secondary receptor for bacteriophages, making it a key target in phage therapy. It is also highly immunogenic and has been investigated as a candidate antigen for DNA and multi-epitope vaccines to prevent Klebsiella infections.
Serves as a passive diffusion channel for beta-lactam antibiotic entry, a target antigen for vaccine-induced antibodies, and a receptor for bacteriophage binding.
10 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Outer membrane protein OmpK36 (OmpK36).